Catabasis Pharmaceuticals, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Catabasis Pharmaceuticals, Inc. - overview
Established
2008
Location
Boston, MA, US
Primary Industry
Biotechnology
About
Based in Massachusetts, US and founded in 2008, Catabasis Pharmaceuticals, Inc. develops a monoclonal antibody inhibitor of plasma kallikrein as a drug for patients with Hereditary Angioedema, a rare genetic disorder. Founded by Jill Milne, Ph. D.
, the company raised funding in 2010 and 2011 from Advanced Technology Ventures, Clarus Ventures, MedImmune Ventures, and SV Health Investors. In 2012, Catabasis Pharmaceuticals, Inc. raised funding from Muscular Dystrophy Association, and in 2013, Advanced Technology Ventures, Clarus Ventures, Lightstone Ventures, MedImmune Ventures, and SV Health Investors invested in the company. The company works with pharmaceutical companies, by offering the drug application for patients with hereditary angioedema and dyslipidemias.
Catabasis Pharmaceuticals, Inc. develops QLS-215, a monoclonal antibody inhibitor of plasma kallikrein that helps patients build protective protein produced by the immune system from rare genetic disorders. The pharmaceutical institutions will approach the company by checking the process and effects of the drug during the clinical trial. If accepted, pharmaceuticals will then purchase the drug and manufacture it for public consumption through drug stores.
The company generates revenue by offering their drug application intended for patients with rare genetic disorders such as hereditary angioedema and dyslipidemias to pharmaceutical institutions. The company plans to file the new drug application for QLS-215 in 2022 and initiate a phase 1 clinical trial in late 2022.
Current Investors
Advanced Technology Ventures, SV Health Investors, Clarus Ventures
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.catabasis.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.